The purpose of the study is to see how well the combination treatment works compared to the single medication in preventing the return of melanoma after it has been surgically removed. Participants in the study will be randomly assigned to receive either the combination treatment or the single medication. Some participants may receive a placebo, which is a substance with no active medication. The study will last for up to 12 months, during which time participants will receive regular infusions and be monitored for any changes in their condition.

Throughout the study, researchers will keep track of how long participants remain free from melanoma returning, as well as other important health outcomes. These include how long participants live without the cancer spreading to other parts of the body, overall survival rates, and any side effects experienced. The study will also assess changes in participants’ quality of life and physical functioning. This information will help determine the effectiveness and safety of the combination treatment compared to the single medication.

The study has more than one part. In the first part, small groups of people receive the drug combinations so that researchers can watch for side effects and choose a dose that can be used more widely. In the later part, more people receive the combinations to learn more about how the treatment works in the different cancer groups and to compare dose options in some groups. Because this is an open-label trial, everyone knows which treatment is being given.

During the trial, the treatment is given over time, and participants are followed closely while they are receiving it and for a period afterward. Doctors check for side effects, how well the cancer seems to respond, and how the body handles the drugs. The study includes people with several cancer types, and the treatment plan may differ depending on the cancer group and the study part.

The study is done in two parts. In the first part, different doses of REGN10597 are tested alone and with cemiplimab to see how people tolerate the treatment. In the second part, more people receive the study treatment to learn more about its effect on the cancer. Participants are followed over time while the medicines are given and after treatment ends.

People who join this study must have already received at least one dose of RP1, RP2, or RP3 in a previous study and have either finished that study or stopped participating in it. During this study, doctors will watch for specific types of delayed health problems that might be related to the treatment. These include new cancers, new or worsening problems with the nervous system (which controls things like movement and sensation), new or worsening problems with the immune system (which protects the body from disease) or conditions where the immune system attacks the body itself, new blood disorders, new infections related to the treatment, and new infections caused by the herpes virus.

The study will follow patients for several years to collect information about their health and any new medical problems that develop. This helps researchers understand if there are any long-term effects from treatment with these experimental medicines. Patients will be asked to report any new health issues to their doctors, who will record this information as part of the study.

The purpose of this study is to compare how MB11 and Opdivo work in the body, how well they control the cancer, how safe they are, and how the body’s immune system responds to them. The study wants to show that MB11 works in a similar way to Opdivo when used as the first treatment for people with melanoma that cannot be removed by surgery or has spread to other parts of the body.

During the study, participants will be randomly assigned to receive either MB11 or Opdivo. Neither the participants nor the doctors will know which medicine is being given. The treatment will be given regularly over a period of time, and participants will be monitored through regular visits where blood samples will be taken, scans will be performed to check how the cancer is responding, and any side effects will be recorded. The study will also check if the body develops an immune response to the medicine. Participants will continue to be followed for their health and survival even after the treatment period ends.

The purpose of this study is to see how well lifileucel works in shrinking or stopping the growth of melanoma tumors in people who have already been treated with other therapies. The study will measure how many people have their tumors shrink or disappear completely after receiving lifileucel. It will also look at how long the treatment response lasts, how long people live without their cancer getting worse, overall survival, and the safety of the treatment.

During the study, people will first have surgery to remove a tumor or part of a tumor so that the immune cells can be collected and grown in the laboratory. After the tumor is removed, people will wait while the lifileucel is being prepared. Once ready, they will receive the chemotherapy medicines cyclophosphamide and fludarabine phosphate through a vein over several days to prepare their body. Then they will receive a single infusion of lifileucel. Following this, they will receive aldesleukin through a vein to help support the infused cells. After treatment, people will be monitored regularly with scans and tests to see how their cancer responds and to check for any side effects. The study will continue to follow people for up to five years after they receive the lifileucel infusion.

The purpose of this study is to investigate the cardiovascular side effects of immune checkpoint inhibitors, which means looking at how these cancer treatments might affect the heart and blood vessels. The study will monitor patients who are receiving these treatments as part of their regular cancer care. During the study, doctors will check for various heart-related problems that might develop or get worse during treatment. The treatment period with these medicines can last up to twelve months.

The main focus of the study is to track serious heart-related events, including death from heart problems, heart attacks, strokes, chest pain that requires hospital care or urgent treatment to restore blood flow to the heart, and hospital stays due to heart failure (when the heart cannot pump blood well enough). The study will also look at other heart and blood vessel problems such as new or worsening high blood pressure, irregular heartbeats, blood clots in the veins, and other heart-related issues that require hospital admission. This research aims to better understand how these cancer treatments affect the heart and blood vessels so that doctors can better monitor and care for patients receiving these medicines.

The purpose of this study is to evaluate how well acasunlimab works against tumors when given alone and when given together with pembrolizumab. The study will also look at the safety of these treatments. The main way the study will measure how well the treatments work is by checking how many people have their tumors shrink or disappear after receiving the treatment. This will be done using imaging scans that are evaluated according to standard criteria for measuring tumor response.

During the study, participants will receive their assigned treatment through infusions into a vein. The treatment may continue for up to 36 months depending on how well it works and how well it is tolerated. Throughout the study, doctors will regularly monitor participants with physical examinations, blood tests, and imaging scans to check how the cancer is responding to treatment and to watch for any side effects. The study is expected to begin enrolling participants in late 2025 and continue until mid-2029.

The study will track patients who previously received treatment with LIBTAYO (also known as cemiplimab) and fianlimab (also known as REGN3767). These medications belong to a group of biological or biotechnology-derived treatments. The medications work together to help the body’s immune system fight against melanoma cells.

During this extended follow-up study, researchers will monitor patients’ overall survival and track how their disease responds to treatment over time. The study will also collect information about any health issues that may occur and any additional cancer treatments that patients receive after their initial treatment. This long-term monitoring will help understand how patients respond to the treatment combination over an extended period.

The study focuses on patients whose melanoma cannot be surgically removed or has spread to other parts of the body. Patients with brain metastases (cancer that has spread to the brain) may participate if these metastases are asymptomatic or have been treated. The purpose is to determine if the IOpener-melanoma test can accurately predict which patients will benefit from combination therapy or monotherapy with immune checkpoint inhibitors.

During the study, participants will receive treatment based on their IOpener-melanoma test results. The study will track how patients respond to treatment, including how long they live without their disease getting worse, overall survival, and quality of life measures.

The study is designed as a Phase 2 clinical trial that will randomly assign participants to receive either V940 plus pembrolizumab or placebo plus pembrolizumab. Participants will need to have at least one measurable tumor that can be detected by computed tomography (CT scan) or magnetic resonance imaging (MRI). They will also need to provide tumor tissue samples for genetic analysis and biomarker testing. The trial will measure how long participants live without their cancer getting worse, as well as other factors like tumor response rates and overall survival.

The purpose of the study is to compare survival outcomes between patients receiving the VO and nivolumab combination versus standard treatments chosen by doctors. During the study, patients will be randomly assigned to receive either the combination therapy or the physician’s choice of treatment. Patients will undergo regular assessments to monitor how their cancer responds to treatment and to check for any side effects.

The purpose of the study is to find out the highest concentration of these biotherapy drugs that can be used in skin tests without causing irritation in patients who are not allergic. The study will involve skin tests, such as prick tests and intradermal tests, to check for any allergic reactions. Patients who have been treated with these biotherapies and have not shown any allergic reactions will be part of the study. The study will monitor for any immediate or delayed skin reactions after the tests.

Throughout the study, patients will be contacted to confirm if there are any delayed reactions, which might occur up to a week after the skin tests. If a reaction is suspected, a photograph or video consultation with an allergist may be used to confirm it. The study aims to ensure that the skin tests are safe and do not cause unnecessary irritation to patients undergoing biotherapy treatments.

The purpose of the study is to see how well pembrolizumab works in shrinking the melanoma before surgery. Participants in the study will receive pembrolizumab as a neoadjuvant treatment, which means it is given before the main treatment, in this case, surgery. The study will monitor the response of the melanoma to the treatment, looking for a major pathological response, which means a significant reduction in cancer cells in the tumor. The study will also track any side effects or adverse events that participants may experience during the treatment.

Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the progress of the treatment. The study will also evaluate the long-term outcomes for participants, such as event-free survival, which is the time from the start of treatment until the cancer progresses or other significant events occur. The study is expected to continue until 2029, providing valuable information on the effectiveness and safety of pembrolizumab as a treatment for high-risk cutaneous melanoma.

Participants in the study will receive treatments through an intravenous infusion, which means the medicine is given directly into a vein. The study will include several medications, such as pembrolizumab, temozolomide, paclitaxel, nivolumab, ipilimumab, carboplatin, and dacarbazine. These medications are commonly used in cancer treatment and work in different ways to help fight cancer cells. Some participants may receive a placebo, which is a substance with no active medication.

The study will last for a period of time, during which participants will be monitored for their response to the treatment and any side effects. The aim is to gather information on how well the treatments work and how safe they are for patients with previously treated, unresectable, or metastatic cutaneous melanoma.

The purpose of the study is to evaluate how well these medications work together in preventing the cancer from getting worse in the brain over a period of six months. Participants will first receive Encorafenib and Binimetinib for a set period, and then switch to receiving Cemiplimab and Fianlimab. The study will monitor the participants’ health and the progression of their cancer during this time.

Throughout the study, participants will have regular check-ups and tests to track their response to the treatment. The study aims to provide valuable information on the effectiveness of this treatment combination for patients with BRAF-mutated melanoma and brain metastases, which are cancer cells that have spread to the brain. The results could help improve future treatment options for this condition.

The purpose of the study is to validate the effectiveness of this hybrid tracer in accurately identifying sentinel nodes. The study will compare the results of using the hybrid tracer with the standard method, which uses only Technetium (99mTc) Nanocolloid. Participants will receive an injection of the tracer substances, and imaging techniques such as lymphoscintigraphy and SPECT/CT will be used to visualize the sentinel nodes before surgery. The study aims to ensure that the hybrid tracer can reliably identify the same number of sentinel nodes as the standard method.

Throughout the study, researchers will monitor the number and intensity of the nodes detected by both the hybrid tracer and the standard method. This will help determine if the new method is as effective as the current standard in identifying sentinel nodes. The study is expected to provide valuable information that could improve the accuracy of sentinel node biopsies in patients with these types of cancer.

The purpose of the study is to see how well the [68Ga]Ga-FAPI-46 PET/CT scan can detect changes in cancerous lesions compared to the standard imaging method using [18F]FDG. The study will also look at how these changes relate to the patient’s clinical response to the treatment. Participants will undergo these imaging scans during their treatment to monitor the effectiveness of the therapy.

Additionally, the study will explore how the uptake of [68Ga]Ga-FAPI-46 in healthy tissue might predict potential side effects. Researchers will compare these findings with standard imaging results and analyze blood samples to understand the relationship between the tracer uptake and various biomarkers, which are substances in the blood that can indicate disease activity or response to treatment. The study aims to provide better and faster imaging options for patients with advanced malignant melanoma.

The purpose of this study is to see how effective pembrolizumab is in treating high-risk melanoma before any surgery is done to remove the cancer. This approach is known as “neoadjuvant” treatment, which means the treatment is given before the main treatment, usually surgery, to help shrink the tumor and make it easier to remove. The study will monitor how well the treatment works by checking if the cancer has spread to nearby lymph nodes, which are small glands that help fight infection and are often the first place cancer spreads.

Participants in the study will receive pembrolizumab over a period of time, and doctors will perform regular check-ups and tests to see how the cancer responds to the treatment. The study will also look at the overall health and quality of life of the participants during the treatment. This research aims to provide more information on how pembrolizumab can be used effectively in treating high-risk melanoma and improve outcomes for patients with this type of cancer.

The purpose of the study is to observe what happens when patients who have shown a complete or partial response to these treatments stop taking them. The study will monitor the ongoing response of the cancer after stopping the medication. Patients will be observed over a period to see if the cancer remains under control without the continued use of the medication.

Participants in the study will have regular check-ups and imaging tests, such as MRI or CT scans, to monitor their condition. The study aims to understand the long-term effects of stopping treatment and whether the cancer remains stable or progresses. This information could help in making future treatment decisions for patients with advanced melanoma.

Participants in the study will receive the treatment over a period of time, with regular monitoring to assess how their body responds to the medication. The study will look at both the local effects at the site of the tumor and the overall effects on the body. The goal is to determine the best dose of BT-001 and to see how well it works when used with pembrolizumab. Some participants may receive a placebo as part of the study to help compare the effects of the actual treatment.

Throughout the study, participants will undergo various assessments to monitor their health and the progression of their cancer. This includes regular check-ups and tests to ensure the treatment is safe and to measure its impact on the cancer. The study aims to provide valuable information on the potential benefits of combining BT-001 with pembrolizumab for treating these challenging types of cancer.

Participants in the study will receive the treatment through intravenous administration, meaning it will be delivered directly into the bloodstream. The study is divided into two phases. In the first phase, the focus is on determining the safety and the best dose of the MC2 TCR T cells when used with the epigenetic drug. The second phase will assess how well the treatment works in shrinking or controlling the cancer. Throughout the study, doctors will monitor for any side effects and measure how the cancer responds to the treatment.

The trial aims to find out if this new approach can be a viable option for patients with these types of cancer, especially those who have not responded to standard treatments. By using the patient’s own immune cells, which are modified to better fight the cancer, the study hopes to offer a more personalized treatment option. The results will help determine if this therapy can be used more widely in the future for treating advanced melanoma and HNSCC.

The purpose of the study is to evaluate how well CEUS can identify sentinel nodes during surgery compared to the current standard method. Participants will undergo a procedure where the Sonazoid contrast agent is injected, and the sentinel nodes are then located using the CEUS technique with the help of a device called the BK5000 US device. This study aims to determine the accuracy of CEUS in finding these nodes and to see if it can predict whether the nodes are cancerous.

Throughout the study, researchers will monitor the time it takes to locate the sentinel nodes using CEUS and assess the ease of using the CEUS system. The study will provide valuable information on whether this method can be a reliable alternative to existing techniques for detecting sentinel nodes in patients with these types of cancer.

The purpose of the study is to see if using IMO-2125 can reduce the number of cancerous cells found in a specific type of lymph node, called the sentinel lymph node (SLN), in patients with this stage of melanoma. The study will compare the effects of IMO-2125 with a placebo to determine its effectiveness. Participants will receive the treatment and then be monitored for changes in their condition, including the presence of cancer cells in the SLN, over a period of time.

Throughout the study, researchers will also observe other factors, such as the activity of certain immune cells in the lymph nodes and blood, and track the participants’ health over several years. This includes looking at how long patients remain free of cancer and their overall survival rates at different time points after the treatment. The study aims to provide valuable information on whether IMO-2125 can be an effective treatment option for this type of melanoma.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The purpose of this study is to find the best dose of Fianlimab and the best time to perform a special type of imaging called PET scan to see how the treatment is working. A PET scan is a test that helps doctors see how organs and tissues inside the body are functioning. The study will also look at how safe Fianlimab is for patients. Participants will receive the treatment and undergo PET scans before and during their treatment with Cemiplimab, with or without chemotherapy. The study will help researchers understand how the treatment affects the body and how well it works against the cancer.

Throughout the study, patients will be monitored closely to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information that could lead to better treatment options for people with advanced solid cancers. By understanding how these medications work together, researchers hope to improve outcomes for patients facing these challenging diseases.

The purpose of this study is to compare the effects of continuing standard immunotherapy with a reduced dose of the same treatment. The medications being studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Some patients will receive the standard dose of these medications, while others will receive a reduced dose every three months.

The study will last for up to three years, during which time patients will continue to receive their assigned treatment. The main goal is to see if the reduced dose is as effective as the standard dose in keeping the cancer from getting worse. Patients will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study will also look at other factors, such as the quality of life and any side effects experienced by the patients. This research aims to find the best way to use immunotherapy to treat cancer effectively while minimizing side effects.

Participants in the study will receive either ceralasertib by itself or ceralasertib together with durvalumab. Ceralasertib is taken as a tablet, while durvalumab is given through an infusion, which means it is delivered directly into the bloodstream. The study will last for up to 22 months, during which time the response of the cancer to the treatments will be monitored. Some participants may also be part of a sub-study that involves taking small samples of their tumor tissue to see how the treatments affect certain immune cells.

The trial aims to understand the changes in the tumor and the immune system caused by the treatments. This includes looking at how many patients show a reduction in tumor size and how long any positive effects last. The study will also measure the presence of certain immune cells, like CD8+ T cells, in the tumor before and after treatment. This research could provide valuable insights into new ways to treat melanoma that has not responded to other therapies.

Participants in the study will be randomly assigned to one of two groups. One group will receive nivolumab, while the other group will be observed without receiving the medication. The study will follow participants over time to see if the melanoma returns or if there are any other health changes. The main focus is on how long participants remain free from melanoma returning, which is referred to as Relapse-Free Survival (RFS). The study will also look at other outcomes, such as how long participants live without the cancer spreading to other parts of the body, known as distant metastasis-free survival, and overall survival rates.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the status of their melanoma. The study aims to provide valuable information on whether nivolumab can help prevent the return of melanoma in patients who are at high risk, potentially offering a new treatment option for this group. The study is expected to continue until 2027.

Participants in the study will receive a reduced dose of nivolumab, administered through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the levels of the drug in the body to ensure they remain effective while using a lower dose. This approach aims to maintain the benefits of the treatment while potentially reducing side effects and costs.

The study will take place over a period of time, with regular assessments to check the drug levels and monitor any side effects. The goal is to determine if the reduced dose can maintain the same level of effectiveness as the higher dose previously used. This research could lead to improved treatment strategies for patients with melanoma and renal cell carcinoma, making their therapy more manageable and cost-effective.

The purpose of the study is to evaluate how effective these treatments are for patients who need steroid medication due to brain metastases. The trial will observe patients over a period to see how well the treatments work in controlling the cancer and improving survival rates. Participants will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will monitor the patients’ health and response to the treatment over time.

Throughout the study, researchers will look at various outcomes, such as how long patients live without the cancer getting worse and the overall survival rate. They will also assess the response of the cancer both inside and outside the brain. The study aims to provide valuable information on the effectiveness of these immunotherapy treatments for patients with melanoma that has spread to the brain.

Participants in the study will receive the medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor patients over time to see how their cancer responds to the treatment and whether the response continues after stopping nivolumab. The study will also look at the overall survival of patients and their quality of life during and after the treatment. Patients will be asked to fill out questionnaires about their quality of life at various points during the study.

The study will last for several years, with regular check-ups to assess the ongoing response to the treatment. The researchers aim to determine if stopping nivolumab early can still provide long-term benefits for patients with advanced melanoma. This information could help improve treatment plans for future patients with this type of cancer.

The purpose of the study is to compare the combination of naporafenib and trametinib with other treatments chosen by doctors, which may include dacarbazine, temozolomide, or trametinib alone. Dacarbazine and temozolomide are chemotherapy medications that work by damaging the DNA of cancer cells, preventing them from growing. The study will begin with a phase to determine the best dose of the naporafenib and trametinib combination. After this, the main part of the study will compare how well patients do on the combination treatment versus the other treatment options.

Participants in the study will receive their assigned treatment and be monitored over a period of time to assess the effects on their cancer. The study will look at how long patients live without their cancer getting worse and their overall survival. The trial will also monitor the safety of the treatments and any side effects that may occur. This research aims to find the most effective treatment option for patients with this specific type of melanoma.

The purpose of this research is to determine if using MaaT013 together with ipilimumab and nivolumab is safe and well-tolerated by patients with melanoma who have not previously received these cancer treatments. The study will compare patients who receive MaaT013 with those who receive a placebo in combination with their cancer medications.

The treatment period lasts 23 weeks, during which patients will receive either MaaT013 or placebo along with their regular cancer medications. Throughout the study, doctors will monitor patients’ health and how their cancer responds to the treatment. The total observation period extends to 27 weeks to assess the overall effects of the treatment combination.

The purpose of the study is to determine how well these treatments work in eliminating cancer cells before and after surgery. Participants will receive these medications in different sequences or combinations. Vemurafenib and cobimetinib are taken orally as tablets, while atezolizumab is given through an intravenous injection, which means it is administered directly into a vein. The study will monitor the response of the cancer to these treatments over a period of time, aiming to see if the cancer can be completely removed or reduced significantly.

Throughout the study, researchers will also observe the safety of the treatments and any changes in the cancer or the patient’s immune system. The study will track how long patients remain free from cancer recurrence and overall survival rates. This information will help in understanding the effectiveness of the treatment combinations and their impact on patients with melanoma.

The study will be conducted in two phases. In the first phase, the focus will be on comparing the combination of Fianlimab and Cemiplimab to Cemiplimab alone to see how well they work as a treatment before and after surgery. The second phase will assess how long patients remain free of events like cancer recurrence when treated with the combination of Fianlimab and Cemiplimab compared to Pembrolizumab alone. The trial will involve regular monitoring and assessments to ensure the safety and effectiveness of the treatments.

Participants in the study will receive their assigned treatment and undergo various evaluations, including imaging tests like MRI to monitor the progress of their condition. The trial will help determine the best dose of Fianlimab to use in combination with Cemiplimab for future treatments. The study is expected to provide valuable information on the potential benefits of combining these medications for patients with resectable melanoma.

The purpose of the study is to understand how the uptake of [18F]F-AraG changes in tumor lesions after radiotherapy. This will help researchers learn more about how cancer cells respond to treatment. Participants in the study will receive radiotherapy and will undergo imaging scans to track the uptake of the imaging agent in their tumors. These scans will be done at different times to see how the uptake changes over time.

Throughout the study, participants will continue their ongoing treatment with immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer. The study aims to provide valuable insights into the effectiveness of radiotherapy in combination with immunotherapy by using the [18F]F-AraG imaging agent to monitor changes in the cancer cells. This research could lead to better understanding and improvements in cancer treatment strategies.

Participants in the study will receive the medications through an infusion, which means the drugs are given directly into the bloodstream. The study will observe how the tumors respond to the treatment over a period of time. The trial is designed to see if the combination of Tiragolumab and Tecentriq can help shrink the tumors or stop them from growing. The study will also monitor the safety of the medications and any side effects that may occur.

The trial is open-label, meaning both the researchers and participants know which treatment is being administered. The study will include different groups of patients, each with specific types of cancer, to determine the effectiveness of the treatment across various conditions. The trial aims to provide valuable information on whether these medications can be beneficial for patients with these types of cancer.

Participants in the study will receive their assigned treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for up to 24 months, during which time patients will be monitored for their overall health and any side effects they might experience. The study will also look at how the body processes the medicine and any changes in the patient’s condition over time.

In addition to tebentafusp, the study involves other medications such as dacarbazine, pembrolizumab (known as Keytruda), and ipilimumab (known as Yervoy). These medications are also given through intravenous infusion and are part of the treatment options that doctors may choose for patients in the study. The study aims to provide valuable information on the safety and effectiveness of these treatments for patients with advanced uveal melanoma.

The purpose of this study is to understand which form of Pembrolizumab patients prefer. Participants will receive both forms of the medication during the study. They will be asked to share their preferences and satisfaction with each method of receiving the treatment. The study will also monitor any side effects that participants may experience. This information will help doctors understand which method of treatment is more comfortable and preferable for patients.

Throughout the study, participants will be asked to complete questionnaires about their experiences and preferences. The study aims to gather information on how patients feel about the convenience and comfort of each treatment method. This will help improve the way cancer treatments are given in the future, making them more patient-friendly. The study is expected to continue until 2026, providing valuable insights into patient preferences for cancer treatment administration.